Skip to main content

and
  1. No Access

    Article

    Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup

    Rurioctacog alfa pegol (Adynovate) is a modified recombinant factor VIII concentrate used for treating hemophilia A. Aiming to improve treatment tailoring on the Web-Accessible Population Pharmacokinetic Servi...

    Pierre Chelle, Cindy H. T. Yeung, Stacy E. Croteau in Clinical Pharmacokinetics (2020)

  2. No Access

    Article

    Availability of angiography and therapeutic embolization for the treatment of acute bleeding in patients with hemophilia

    Clotting factor replacement therapy alone is often inadequate for acute bleeding in hemophilia patients, and surgery for such patients poses significant clinical challenges. Arterial angiographic intervention ...

    Mi ** Kim, Ji Young Oh, Young Shil Park in International Journal of Hematology (2017)

  3. Article

    Open Access

    Comparison of continuous infusion versus bolus injection of factor concentrates for blood management after total knee arthroplasty in patients with hemophilia

    Total knee arthroplasty (TKA) has become the treatment of choice for end-stage hemophilic arthropathy of the knee. Theoretically in hemophilia A, perioperative continuous infusion (CI) of factor VIII (FVIII) w...

    Young Shil Park, Won-Ju Shin, Kang-Il Kim in BMC Musculoskeletal Disorders (2017)

  4. No Access

    Article

    Clinical Characteristics and Prognostic Factors in Hemophiliacs with Intracranial Hemorrhage: A Single-Center, Retrospective Experience

    Intracranial hemorrhage (ICH) is the most serious bleeding event that occurs in patients with hemophilia; its estimated mortality rate is approximately 20 %, accounting for the largest number of deaths from bl...

    Jung Yoon Cho, Won Seok Lee, Young Shil Park in Indian Journal of Hematology and Blood Tra… (2016)